Medtronic (MDT) said Sunday that data from a 1,414 study of its Evolut transcatheter aortic valve replacement device in patients with severe aortic stenosis showed numerically lower mortality or disabling stroke rates, "strong" valve performance and durable clinical outcomes compared with surgery at five years.
The company said 15.5% of patients with severe aortic stenosis who were treated with the Evolut device experienced all-cause mortality or a disabling stroke at five years, compared with 16.4% for surgery, while 7.2% of Evolut patients and 9.3% of surgery patients suffered death due to heart failure.
Severe aortic stenosis is a heart condition in which the aortic valve is so narrowed that it cuts off blood flow from the heart to the body.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.